Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients

Background: Pancreatic cancer carries a devastating prognosis and is the fourth leading cause for cancer-related death in the United States and most European countries. Although one-third of patients receive a palliative third line therapy, the benefit of systemic therapy beyond second-line remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlick, Konstantin, Kiem, Dominik, Huemer, Florian, Neureiter, Daniel, Weiss, Lukas, Greil, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489749/
https://www.ncbi.nlm.nih.gov/pubmed/34595977
http://dx.doi.org/10.1177/15330338211042139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489749/
https://www.ncbi.nlm.nih.gov/pubmed/34595977
http://dx.doi.org/10.1177/15330338211042139

Ejemplares similares